Want to join the conversation?
$AOS used available borrowing capacity on its $400MM revolving credit facility to fund the $87MM debt-free acquisition. $AOS believes Aquasana's organic revenue, including synergies, could reach $100MM in 2019. The transaction is expected to achieve a return in excess of $AOS' cost of capital in the third year after completing the acquisition.
$BABA seems to be on a roll! But increasing its yearly sales outlook from 48% to 54% seems over-expectation from the company's part, doesn't it?
$JNJ down 2% in pre-market trading. Earnings beat expectations, but sales disappointed. Johnson is cautious on its outlook. How it will perform in the future?